Extendicare Announces Timing of 2021 Fourth Quarter Results and Year End Results and Conference Call
MARKHAM, Ontario, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the fourth quarter and year ended December 31, 2021 after market close on Thursday, February 24, 2022. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Senior Vice President and Chief Financial Officer, will be held on Friday, February 25, 2022, at 11:30 a.m. (ET) to discuss the results.
To participate in the conference call on February 25, 2022, please dial 1-800-319-4610 or 416-915-3239. The conference call and accompanying slide presentation will also be accessible via webcast at www.extendicare.com under the “Our Investors/Events & Presentations” section. A replay of the call will be available approximately two hours after completion of the live call until midnight on March 11, 2022. To access the rebroadcast dial 1-800-319-6413 followed by the passcode 8379#.
Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, Esprit Lifestyle, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. We are committed to delivering quality care throughout the health continuum to meet the needs of a growing seniors population. We operate or provide contract services to a network of 120 long-term care homes and retirement communities (69 owned/51 contract services), provide approximately 9.0 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 88,400 senior residents across Canada. Extendicare proudly employs more than 23,500 qualified, highly trained and dedicated individuals who are passionate about providing high quality care and services to help people live better.
- MEDIROM Healthcare Technologies Inc. Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
- Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin
- Treatment Launches Landmark Doctor Built Digital Health App